HOME >> MEDICINE >> NEWS
U.S., British scientific societies honor penicillin as International Chemical Landmark

The development of penicillin, one of the 20th century's greatest lifesavers, will be honored as an International Historic Chemical Landmark at 11a.m. Friday, Nov. 19 in London. The designation takes place 70 years after the discovery of the drug was first published by Alexander Fleming.

Representatives from the government, academic and private sector research teams that helped move Fleming's discovery from the lab to the hospital will be reunited in London for the designation of the landmark by the Royal Society of Chemistry and the Washington, D.C.-based American Chemical Society. The last surviving member of the original research team, biochemist Norman Heatley of Oxford University, will be a special guest at the ceremony, to be held at Fleming's laboratory in St. Mary's Hospital, London.

While Fleming's identification of penicillin and its potential uses was first published in 1929, development of a viable drug and the ability to mass-produce it during World War II proved tougher obstacles to surmount. Researchers from Oxford University in England were able to test penicillin in mice and in humans, then sought wartime help in funding, further research, and manufacturing from U.S. government agencies, academic institutions and pharmaceutical company labs. The resulting teamwork was carried forward when, after the U.S. entry into World War II, the government recruited more than 20 chemical companies to mass-produce the drug. The result: Deaths from infected wounds during the war were virtually eliminated, as 95 percent of the wounded soldiers survived.

The American Chemical Society designates important steps in the evolution of chemical science and technology as Historic Chemical Landmarks. "The landmarks program reminds us of the grandeur of chemistry, while underlining that chemistry is a very human enterprise, filled with all triumphs and setbacks of men and women trying to understand the world and make it better," said Ed Wasserman,
'"/>

Contact: Kathleen Milanich
k_milanich
202-872-4493
American Chemical Society
14-Nov-1999


Page: 1 2

Related medicine news :

1. Sepsis on the increase in U.S., according to Emory University and CDC study
2. U.S., Mexican scientific societies honor former Penn State professor
3. British hospitals need clinical ethicists
4. Concerns over the future of childrens health care in British general practice
5. British conservatives should beware of Australian health service reforms
6. Heart disease risk in British men is overestimated
7. US women endure twice the surgical biopsies as British for same cancer detection rate
8. British scientists receive Lasker Prize for discovering new treatment for rheumatoid arthritis
9. British public supports mercy killing
10. British Adolescents Need Government Support To Help Clean Up Their Act
11. Public morally obliged to take part in scientific research, says leading ethicist

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: